USFDA29 May 2025, 06:02 pm
Orchid Pharma Ltd Receives USFDA's EIR for Alathur Plant
AI Summary
Orchid Pharma Ltd has announced the receipt of the Establishment Inspection Report (EIR) from the USFDA for its plant located at Alathur. The EIR has been issued with 'VAI' status, indicating the acceptance of the company's submission on the earlier raised observations. This recognition reaffirms Orchid Pharma's compliance with USFDA regulatory standards, underscoring the company's commitment to quality and excellence in pharmaceutical manufacturing.
Key Highlights
- Orchid Pharma Ltd receives EIR from USFDA for its Alathur plant
- EIR issued with 'VAI' status, signifying acceptance of company's submission on earlier observations
- Recognition reaffirms Orchid Pharma's compliance with USFDA regulatory standards
- Company's commitment to quality and excellence in pharmaceutical manufacturing reinforced
- Orchid Pharma's Alathur plant now compliant with USFDA regulatory standards